{
    "body": "Describe the mechanism of action of drisapersen", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25209738", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24292388", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24620745", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23995279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24321374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24229740"
    ], 
    "ideal_answer": [
        "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. It has potential for treatment of Duchenne muscular dystrophy."
    ], 
    "type": "summary", 
    "id": "54fc98f16ad7dcbc12000003", 
    "snippets": [
        {
            "offsetInBeginSection": 167, 
            "offsetInEndSection": 319, 
            "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 205, 
            "text": "UNLABELLED: Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in renal tubular accumulation, with secondary tubular degeneration.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292388", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 544, 
            "offsetInEndSection": 646, 
            "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 509, 
            "offsetInEndSection": 610, 
            "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 167, 
            "offsetInEndSection": 317, 
            "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 404, 
            "offsetInEndSection": 664, 
            "text": "Fast forward 25 years, and two phase 2b/3 trials have been carried out with agents designed to induce de novo dystrophin production in DMD patient's muscle; ataluren (stop codon read through) with 174 patients, and drisapersen (exon skipping) with 186 patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24229740", 
            "endSection": "abstract"
        }
    ]
}